The prospective, multi-site study, entitled “Assessing the Impact of Margin Reduction (AIM),” is the first outcome-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.” The findings of the AIM study, which are published in Urology (The GOLD JOURNAL), demonstrate that the use of the Calypso® System during high-dose external beam radiation for prostate cancer resulted in a significant reduction in rectal and urinary treatment-related side effects.

The Calypso® System delivers precision and accuracy—continuously and in real time—enabling radiation oncology clinicians to keep the target in the path of the radiation beam at all times. By detecting the slightest tumor movement—and enabling the patient to be repositioned if necessary—the Calypso System helps clinicians deliver maximum radiation directly to the tumor while avoiding healthy surrounding tissues and organs.

Clinical Education

Clinical research demonstrates that tracking prostate motion during radiation therapy allows a reduction in the planning target volume (PTV), resulting in fewer patient-reported side effects. Summaries of our clinical research highlights, clinical presentations and other materials have been assembled to demonstrate how to incorporate real-time tracking into your treatment regimen and to increase the quality of life for your patients.

Calypso's robust clinical biography includes peer-reviewed articles and abstracts that have been presented at major medical meetings throughout the world.

White Papers and Clinical Case Studies 

A library of white papers and clinical case studies provides a range of clinical applications utilizing the Calypso System and describes unique benefits your practice or care center may offer.

Events

Calypso Medical will be present at the following events. Please stop by to learn the latest news and information about our real-time tracking technology. We look forward to meeting you.